now, should we move to a policy where a biosimilar comes out it has to go to an approved fo formu larynopolist will fight. >> first if they are taking advantage of rules in the marketplace that exist. they are adopting rules and taking advantage of them in ways to prevent the competition from entering the market. i think this gets back to what i mentioned before, which is if we had a structure at least in medicare -- medicare is a big purchaser. you look at some of the companies like roche 60%, 70% of their sales into medicare part b. i've seen in analyst reports. they are a big purchaser of these biologics. if we have a scheme in part b like we have in part d where we give preferential treatment to the generics, if you will, biosimilars, you can drive utilization. if you allow formularies to exist in part b, therapeutic sub tugs in part b, even if it isn't interchange later allow formularies to lower cost biosimilar that can create market share. we don't do that right now. medicare is a price taker on all these biologics. when we created part d and b, a and b system, i'm old enough to